New Telomir-1 KDM5 data for Telomir Pharmaceuticals (NASDAQ: TELO)

Rhea-AI Filing Summary

Telomir Pharmaceuticals reported new in vitro pharmacology data for its lead candidate Telomir-1, showing that the drug potently inhibits three members of the KDM5 histone demethylase family. These enzymes help cancers and aging cells silence protective genes and activate harmful inflammatory pathways.

The company notes that Telomir-1 had already demonstrated activity against other histone demethylases, including UTX (KDM6A), JMJD3 (KDM6B), FBXL10 (KDM2B), and FBXL11 (KDM2A), while sparing broad acetyltransferases linked to systemic toxicity. In earlier in vivo prostate cancer studies, Telomir-1 reduced abnormal DNA methylation and reactivated tumor suppressor genes such as CDKN2A and STAT1, with greater activity than chemotherapy and rapamycin.

Taken together, Telomir-1 is described as having broad-spectrum activity across DNA methylation and multiple histone demethylation pathways, supporting ongoing IND-enabling studies, GMP scale-up, and additional preclinical work in aggressive cancers and aging models.

Insights

Biotech and drug development analyst

Preclinical data expand Telomir-1’s epigenetic target profile but remain early-stage.

The update shows Telomir Pharmaceuticals positioning Telomir-1 as a broad epigenetic modulator. In vitro data now include potent inhibition of three KDM5 family members, on top of prior activity against KDM2 and KDM6 enzymes. These targets are described as regulators of tumor suppressor and inflammatory genes, suggesting a mechanistic rationale in cancer and aging.

The company also cites previously reported in vivo prostate cancer studies where Telomir-1 reduced abnormal DNA methylation and reactivated tumor suppressors like CDKN2A and STAT1 with greater activity than chemotherapy and rapamycin. However, all results referenced are preclinical, and no human data are mentioned, so translational relevance is still unproven.

The disclosure ties this biology to ongoing IND-enabling studies and GMP scale-up of Telomir-1, along with additional preclinical work in aggressive cancers and aging models. Subsequent regulatory milestones and clinical trial initiations, when disclosed, will be key to understanding how these findings translate into potential therapeutic benefit.

false 0001971532 0001971532 2025-09-18 2025-09-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 18, 2025

TELOMIR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Florida		001-41952		87-2606031
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

100 SE 2nd St, Suite 2000, #1009

Miami, Florida
(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (786) 396-6723

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, no par value		TELO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies

New in vitro results show Telomir-1 adds KDM5 family inhibition to its previously reported KDM2/KDM6 and DNA methylation activity, potentially representing a novel frontier in epigenetic therapy where no existing candidates have shown comparable breadth.

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) today announced new in vitro pharmacology results demonstrating that Telomir-1 potently inhibits three members of the KDM5 histone demethylase family. Histone demethylases are upstream gene regulators that cancers exploit to silence tumor suppressors and activate inflammatory programs.

In cancer and aging, the silencing of protective genes occurs through two major mechanisms. First, histone demethylases act as switches: proteins of the KDM5 family erase activation marks from tumor suppressor genes and remove repressive marks from genes that drive proliferation and inflammation. Together, these enzymes disable cell-protective pathways and enhance harmful ones. Second, DNA methylation then reinforces the silencing by adding chemical tags to gene promoters, locking tumor suppressors in an inactive state making the silence durable and heritable as cells divide.

In the new in vitro studies carried out by Eurofins Discovery, Telomir-1 inhibited three members of the KDM5 family, thereby blocking the silencing of protective genes and preventing the activation of harmful inflammatory pathways.

In addition to these findings, Telomir-1 has previously demonstrated activity across other families of histone demethylases, including UTX (KDM6A), JMJD3 (KDM6B), FBXL10 (KDM2B), and FBXL11 (KDM2A). These enzymes are associated with cancer progression, stemness, immune evasion, and age-related decline. Telomir-1 was also shown to spare broad acetyltransferases such as GCN5L2, which are associated with systemic toxicity when inhibited.

In other previously reported in vivo prostate cancer studies, Telomir-1 reduced abnormal DNA methylation and reactivated tumor suppressors such as CDKN2A and STAT1, with greater activity than chemotherapy and rapamycin.

Taken together, these results indicate that Telomir-1 has demonstrated broad-spectrum activity across both DNA methylation and several histone demethylation pathways, the two fundamental axes of epigenetic control. The company continues to advance IND-enabling studies and GMP scale-up of Telomir-1, with additional preclinical evaluations ongoing across aggressive cancers and models of aging.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TELOMIR PHARMACEUTICALS, INC.
Dated: September 18, 2025	By:	/s/ Erez Aminov
	Name:	Erez Aminov
	Title:	Chief Executive Officer

FAQ

What did Telomir Pharmaceuticals (TELO) announce about Telomir-1?

Telomir Pharmaceuticals announced new in vitro pharmacology data showing that its lead candidate Telomir-1 potently inhibits three members of the KDM5 histone demethylase family, expanding its epigenetic target profile.

How does Telomir-1 target cancer and aging mechanisms according to TELO?

The company explains that Telomir-1 targets histone demethylases and DNA methylation, two key mechanisms cancers and aging cells use to silence tumor suppressor genes and activate inflammatory pathways, potentially restoring protective gene activity.

Which histone demethylase families does Telomir-1 affect in Telomirs data?

Telomir-1 has shown activity against KDM5 family members in new in vitro studies, and previously against UTX (KDM6A), JMJD3 (KDM6B), FBXL10 (KDM2B), and FBXL11 (KDM2A), which are associated with cancer progression and age-related decline.

What preclinical in vivo results has Telomir reported for Telomir-1?

In earlier in vivo prostate cancer studies, Telomir-1 reduced abnormal DNA methylation and reactivated tumor suppressor genes such as CDKN2A and STAT1, with greater activity than chemotherapy and rapamycin in those models.

Is Telomir-1 being prepared for clinical development by Telomir Pharmaceuticals?

Yes. The company states it is advancing IND-enabling studies and GMP scale-up of Telomir-1, and is running additional preclinical evaluations in aggressive cancer models and models of aging.

How might Telomir-1s selectivity impact safety based on TELOs disclosure?

Telomir Pharmaceuticals reports that Telomir-1 spared broad acetyltransferases such as GCN5L2, which are associated with systemic toxicity when inhibited, suggesting a potentially more favorable selectivity profile in preclinical tests.